Oculis (NASDAQ:OCS) Earns Buy Rating from HC Wainwright

Oculis (NASDAQ:OCS – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued on Tuesday, Benzinga reports. They presently have a $39.00 price target on the stock. HC Wainwright‘s price objective would suggest a potential upside of 427.74% from the company’s current price.

Other research analysts have also recently issued reports about the company. JPMorgan Chase & Co. cut their price objective on Oculis from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Friday, August 14th. Wall Street Zen raised shares of Oculis from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a report on Thursday, October 15th. Finally, Guggenheim dropped their target price on shares of Oculis to $40.00 and set a “buy” rating for the company in a research report on Wednesday, November 4th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $38.57.

Get Our Latest Stock Report on OCS

Oculis Stock Down 1.6%

Shares of OCS opened at $7.39 on Tuesday. The stock has a market cap of $428.47 million, a price-to-earnings ratio of -4.32 and a beta of 0.67. The company has a quick ratio of 10.41, a current ratio of 10.41 and a debt-to-equity ratio of 0.01. Oculis has a 12 month low of $6.78 and a 12 month high of $34.47. The company has a 50-day moving average price of $8.48 and a two-hundred day moving average price of $17.56.

Oculis (NASDAQ:OCS – Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.10. Oculis had a negative return on equity of 39.24% and a negative net margin of 8,613.92%. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.26 million. Equities analysts predict that Oculis will post -1.83 EPS for the current fiscal year.

Institutional Investors Weigh In On Oculis

A number of hedge funds have recently added to or reduced their stakes in OCS. Braidwell LP bought a new position in Oculis in the 2nd quarter valued at $11,570,000. Checkpoint Capital L.P. acquired a new stake in shares of Oculis in the 3rd quarter valued at $929,000. Goldman Sachs Group Inc. increased its stake in shares of Oculis by 103.9% in the 3rd quarter. Goldman Sachs Group Inc. now owns 141,688 shares of the company’s stock valued at $1,323,000 after buying an additional 72,186 shares during the period. Squarepoint Ops LLC raised its position in shares of Oculis by 326.4% during the second quarter. Squarepoint Ops LLC now owns 61,605 shares of the company’s stock worth $854,000 after acquiring an additional 47,158 shares during the last quarter. Finally, Alps Advisors Inc. raised its position in shares of Oculis by 40.7% during the third quarter. Alps Advisors Inc. now owns 81,619 shares of the company’s stock worth $762,000 after acquiring an additional 23,600 shares during the last quarter. Institutional investors own 22.30% of the company’s stock.

Oculis Company Profile

(Get Free Report)

Oculis is a clinical-stage biopharmaceutical company developing treatments for eye diseases. Founded in 2017, the company is headquartered in Switzerland and conducts research and development across multiple locations. Its investigational pipeline includes therapies for conditions such as diabetic macular edema, dry eye disease and optic neuritis. The programs use approaches including topical eye-drop delivery and neuroprotection, with candidates at different stages of clinical development. Oculis focuses on developing treatments for patients worldwide.

Further Reading

Analyst Recommendations for Oculis (NASDAQ:OCS)

Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.